Intrinsiqq
Kailera Therapeutics, Inc. logo

Kailera Therapeutics, Inc. Quality Score

KLRA

Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Cash Flow Multiple
0/100
-9.2x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Capital Structure
100/100
-$535M

Net cash position, no leverage concern

2025
$546M
$11.0M
CashDebt
Return on Capital
0/100
-1163.3%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Kailera Therapeutics (KLRA) quality: score, margins and returns

Kailera Therapeutics (KLRA) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100 and -1,163.3% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Kailera Therapeutics (KLRA) a high-quality business?+

Kailera Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -1,163.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Kailera Therapeutics's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from KLRA's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Kailera Therapeutics scores well and where it falls behind.

What is Kailera Therapeutics's return on invested capital (ROIC)?+

Kailera Therapeutics earns about -1,163.3% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to KLRA's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with KLRA

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Held by ETFs

KLRA is in 9 US ETFs. The largest of them, with KLRA's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing KLRA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.